Loading...
Loading...
NVS| Name | Value |
|---|---|
| Revenues | 13.2B |
| Cost of Revenue | 3.2B |
| Gross Profit | 9.9B |
| Operating Expense | 6.3B |
| Operating I/L | 3.6B |
| Other Income/Expense | -0.2B |
| Interest Income | 0.0B |
| Pretax | 3.4B |
| Income Tax Expense | 0.2B |
| Net Income/Loss | 3.2B |
Novartis AG is a global healthcare company that operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment focuses on prescription medicines across various therapeutic areas such as ophthalmology, neuroscience, immunology, and cardiovascular, among others. The Sandoz segment develops and markets finished dosage form medicines, active pharmaceutical ingredients, and biotechnology-based products, including biosimilars. Novartis also engages in collaborations for drug development and commercialization. The company generates revenue by selling prescription medicines, generics, active pharmaceutical ingredients, and biotechnology products, as well as through collaborations and licensing agreements.
